BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

586 related articles for article (PubMed ID: 26920229)

  • 1. Water-soluble Ru(II)- and Ru(III)-halide-PTA complexes (PTA=1,3,5-triaza-7-phosphaadamantane): Chemical and biological properties.
    Battistin F; Scaletti F; Balducci G; Pillozzi S; Arcangeli A; Messori L; Alessio E
    J Inorg Biochem; 2016 Jul; 160():180-8. PubMed ID: 26920229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CF3 Derivatives of the Anticancer Ru(III) Complexes KP1019, NKP-1339, and Their Imidazole and Pyridine Analogues Show Enhanced Lipophilicity, Albumin Interactions, and Cytotoxicity.
    Chang SW; Lewis AR; Prosser KE; Thompson JR; Gladkikh M; Bally MB; Warren JJ; Walsby CJ
    Inorg Chem; 2016 May; 55(10):4850-63. PubMed ID: 27143338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ru(ii)-(PTA) and -mPTA complexes with N
    Wołoszyn A; Pettinari C; Pettinari R; Badillo Patzmay GV; Kwiecień A; Lupidi G; Nabissi M; Santoni G; Smoleński P
    Dalton Trans; 2017 Aug; 46(30):10073-10081. PubMed ID: 28731114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acetylcholine-like and trimethylglycine-like PTA (1,3,5-triaza-7-phosphaadamantane) derivatives for the development of innovative Ru- and Pt-based therapeutic agents.
    Ferretti V; Fogagnolo M; Marchi A; Marvelli L; Sforza F; Bergamini P
    Inorg Chem; 2014 May; 53(10):4881-90. PubMed ID: 24801393
    [TBL] [Abstract][Full Text] [Related]  

  • 5. trans-thionate derivatives of Pt(II) and Pd(II) with water-soluble phosphane PTA and DAPTA ligands: antiproliferative activity against human ovarian cancer cell lines.
    Guerrero E; Miranda S; Lüttenberg S; Fröhlich N; Koenen JM; Mohr F; Cerrada E; Laguna M; Mendía A
    Inorg Chem; 2013 Jun; 52(11):6635-47. PubMed ID: 23692403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tuning of redox potentials for the design of ruthenium anticancer drugs -- an electrochemical study of [trans-RuCl(4)L(DMSO)](-) and [trans-RuCl(4)L(2)](-) complexes, where L = imidazole, 1,2,4-triazole, indazole.
    Reisner E; Arion VB; Guedes da Silva MF; Lichtenecker R; Eichinger A; Keppler BK; Kukushkin VY; Pombeiro AJ
    Inorg Chem; 2004 Nov; 43(22):7083-93. PubMed ID: 15500346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro and in vivo biological activity screening of Ru(III) complexes involving 6-benzylaminopurine derivatives with higher pro-apoptotic activity than NAMI-A.
    Trávníček Z; Matiková-Mal'arová M; Novotná R; Vančo J; Stěpánková K; Suchý P
    J Inorg Biochem; 2011 Jul; 105(7):937-48. PubMed ID: 21536006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experimental and theoretical investigations of cyclometalated ruthenium(ii) complex containing CCC-pincer and anti-inflammatory drugs as ligands: synthesis, characterization, inhibition of cyclooxygenase and in vitro cytotoxicity activities in various cancer cell lines.
    Tabrizi L; Olasunkanmi LO; Fadare OA
    Dalton Trans; 2019 Jan; 48(2):728-740. PubMed ID: 30560261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and chemical-pharmacological characterization of the antimetastatic NAMI-A-type Ru(III) complexes (Hdmtp)[trans-RuCl4(dmso-S)(dmtp)], (Na)[trans-RuCl4(dmso-S)(dmtp)], and [mer-RuCl3(H2O)(dmso-S)(dmtp)] (dmtp = 5,7-dimethyl[1,2,4]triazolo[1,5-a]pyrimidine).
    Velders AH; Bergamo A; Alessio E; Zangrando E; Haasnoot JG; Casarsa C; Cocchietto M; Zorzet S; Sava G
    J Med Chem; 2004 Feb; 47(5):1110-21. PubMed ID: 14971891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New water-soluble polypyridine silver(I) derivatives of 1,3,5-triaza-7-phosphaadamantane (PTA) with significant antimicrobial and antiproliferative activities.
    Smoleński P; Jaros SW; Pettinari C; Lupidi G; Quassinti L; Bramucci M; Vitali LA; Petrelli D; Kochel A; Kirillov AM
    Dalton Trans; 2013 May; 42(18):6572-81. PubMed ID: 23474654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study of the biological activity of photoactive bipyridyl-Ru(II) complexes containing 1,3,5-triaza-7-phosphaadamantane (PTA).
    Del Pino JMV; Scalambra F; Bermejo-Casadesús C; Massaguer A; García-Maroto F; Romerosa A
    J Inorg Biochem; 2023 Sep; 246():112291. PubMed ID: 37352655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemilabile β-aminophosphine ligands derived from 1,3,5-triaza-7-phosphaadamantane: application in aqueous ruthenium catalyzed nitrile hydration.
    Lee WC; Sears JM; Enow RA; Eads K; Krogstad DA; Frost BJ
    Inorg Chem; 2013 Feb; 52(4):1737-46. PubMed ID: 23356543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes.
    Scolaro C; Bergamo A; Brescacin L; Delfino R; Cocchietto M; Laurenczy G; Geldbach TJ; Sava G; Dyson PJ
    J Med Chem; 2005 Jun; 48(12):4161-71. PubMed ID: 15943488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and structural characterization of copper(I) complexes bearing N-methyl-1,3,5-triaza-7-phosphaadamantane (mPTA): cytotoxic activity evaluation of a series of water soluble Cu(I) derivatives containing PTA, PTAH and mPTA ligands.
    Porchia M; Benetollo F; Refosco F; Tisato F; Marzano C; Gandin V
    J Inorg Biochem; 2009 Dec; 103(12):1644-51. PubMed ID: 19822369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA structural distortions induced by ruthenium-arene anticancer compounds.
    Gossens C; Tavernelli I; Rothlisberger U
    J Am Chem Soc; 2008 Aug; 130(33):10921-8. PubMed ID: 18651736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. cis-Tetrachlorido-bis(indazole)osmium(iv) and its osmium(iii) analogues: paving the way towards the cis-isomer of the ruthenium anticancer drugs KP1019 and/or NKP1339.
    Büchel GE; Kossatz S; Sadique A; Rapta P; Zalibera M; Bucinsky L; Komorovsky S; Telser J; Eppinger J; Reiner T; Arion VB
    Dalton Trans; 2017 Sep; 46(35):11925-11941. PubMed ID: 28850133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis, characterization, and in vitro evaluation of novel ruthenium(II) eta6-arene imidazole complexes.
    Vock CA; Scolaro C; Phillips AD; Scopelliti R; Sava G; Dyson PJ
    J Med Chem; 2006 Sep; 49(18):5552-61. PubMed ID: 16942028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gold(I) complexes with alkylated PTA (1,3,5-triaza-7-phosphaadamantane) phosphanes as anticancer metallodrugs.
    García-Moreno E; Gascón S; Atrián-Blasco E; Rodriguez-Yoldi MJ; Cerrada E; Laguna M
    Eur J Med Chem; 2014 May; 79():164-72. PubMed ID: 24732792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydrolysis of the tumor-inhibiting ruthenium(III) complexes HIm trans-[RuCl4(im)2] and HInd trans-[RuCl4(ind)2] investigated by means of HPCE and HPLC-MS.
    Küng A; Pieper T; Wissiack R; Rosenberg E; Keppler BK
    J Biol Inorg Chem; 2001 Mar; 6(3):292-9. PubMed ID: 11315565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Striking difference in antiproliferative activity of ruthenium- and osmium-nitrosyl complexes with azole heterocycles.
    Büchel GE; Gavriluta A; Novak M; Meier SM; Jakupec MA; Cuzan O; Turta C; Tommasino JB; Jeanneau E; Novitchi G; Luneau D; Arion VB
    Inorg Chem; 2013 Jun; 52(11):6273-85. PubMed ID: 23659478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.